Concepedia

Peter S. Galatin

PS

Statistics

Publications

4

Citations

137

H-Index

4

Active since

2001

Affiliations

Virginia Commonwealth University(Current)

Peter S. Galatin is an author at Virginia Commonwealth University specializing in pharmacology, pharmacophore modeling, and medicine.

Publications per year

2001–2010

4

Publications

4

A Nonpeptidic Sulfonamide Inhibits the p53−mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells

Peter S. Galatin, Donald J. Abraham · Journal of Medicinal Chemistry · 2004 · 90 citations · Full text

, , +8

QSAR: Hydropathic analysis of inhibitors of the p53–mdm2 interaction

Peter S. Galatin, Donald J. Abraham · Proteins Structure Function and Bioinformatics · 2001 · 20 citations

, , +17

A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors

Lee S. Rosen, Peter S. Galatin, J. M. Fehling et al. · Journal of Clinical Oncology · 2008 · 17 citations

, , +14

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

Peter S. Galatin, Ranjana H. Advani, George A. Fisher et al. · Investigational New Drugs · 2010 · 10 citations

, , +10

1–4 of 4